REGENXBIO Inc. (RGNX)

NASDAQ: RGNX · IEX Real-Time Price · USD
27.96 1.38 (5.19%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap1.20B
Revenue (ttm)93.14M
Net Income (ttm)-212.42M
Shares Out42.77M
EPS (ttm)-5.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume442,944
Open26.53
Previous Close26.58
Day's Range26.10 - 28.05
52-Week Range25.80 - 49.63
Beta0.92
AnalystsBuy
Price Target58.33 (+108.6%)
Earnings DateNov 2, 2021

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It i...

IndustryBiotechnology
IPO DateSep 17, 2015
CEOKenneth Mills
Employees306
Stock ExchangeNASDAQ
Ticker SymbolRGNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for REGENXBIO stock is "Buy." The 12-month stock price forecast is 58.33, which is an increase of 108.62% from the latest price.

Price Target
$58.33
(108.62% upside)
Analyst Consensus: Buy

News

REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using...

ROCKVILLE, Md., Jan. 10, 2022 /PRNewswire/ -- ASCENTTM, a Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada Pivotal trials exp...

6 days ago - PRNewsWire

REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne M...

ROCKVILLE, Md., Jan. 6, 2022 /PRNewswire/ -- Potential one-time gene therapy for the treatment of Duchenne includes a novel, optimized microdystrophin transgene and REGENXBIO's proprietary NAV® AAV8 vec...

1 week ago - PRNewsWire

REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

1 month ago - Zacks Investment Research

RegenXbio's Duchenne Gene Therapy Secures FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (Duchenne).  Duchenne is a genetic disorder charact...

1 month ago - Benzinga

REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of D...

ROCKVILLE, Md., Nov. 22, 2021 /PRNewswire/ -- Potential one-time gene therapy for the treatment of Duchenne, includes a novel, optimized microdystrophin transgene and REGENXBIO's proprietary NAV® AAV8 v...

1 month ago - PRNewsWire

REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using ...

ROCKVILLE, Md., Nov. 12, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 in Phase II AAVIATE® trial for the treatment of wet AMD continues to be well tolerated in 50 patients from Cohorts 1-3 wi...

2 months ago - PRNewsWire

REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie

ROCKVILLE, Md., Nov. 9, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a pote...

2 months ago - PRNewsWire

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format:...

2 months ago - PRNewsWire

REGENXBIO Announces RGX-314 Data Presentation at the American Academy of Ophthalmology 2021 Annual Meeting

ROCKVILLE, Md., Nov. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that data from the RGX-314 clinical trials will be presented in an oral presentation at the American Academy of...

2 months ago - PRNewsWire

Regenxbio (RGNX)'s Technical Outlook is Bright After Key Golden Cross

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

2 months ago - Zacks Investment Research

Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -57.47% and -37.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights

ROCKVILLE, Md., Nov. 2, 2021 /PRNewswire/ -- Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining eye care and ge...

2 months ago - PRNewsWire

Can Regenxbio (RGNX) Climb 77% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 77.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positi...

2 months ago - Zacks Investment Research

REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021 Financial Results and Recent Operationa...

ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, November 2, 2021, at 4:30 p.m.

2 months ago - PRNewsWire

Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial

Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME).  The data were prese...

3 months ago - Benzinga

REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retin...

ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 15 patients in Cohort 1 with no drug-related serious adverse events No intraocular inflammation observed...

3 months ago - PRNewsWire

What's Next For REGENXBIO Stock After A 20% Fall Yesterday?

REGENXBIO stock declined by 20% yesterday, while it is down 26% in the last ten trading days. In comparison, the broader S&P500 index declined by 1.4% over the same period.

3 months ago - Forbes

REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using S...

ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Suprachoroidal delivery of RGX-314 well tolerated in 50 patients in Cohorts 1-3 with no drug-related serious adverse events Positive initial data from Cohort...

3 months ago - PRNewsWire

REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting

ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ -- Data for Cohort 1 with three months of follow-up from the RGX-314 Phase II trial for the treatment of diabetic retinopathy (ALTITUDE®) to be presented REGENX...

3 months ago - PRNewsWire

REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call

ROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ -- Interim data for Cohort 1 with six months of follow-up from the RGX-314 Phase II trial for the treatment of wet AMD (AAVIATE®) to be presented REGENXBIO to...

3 months ago - PRNewsWire

AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

Other symbols:ABBV
4 months ago - Zacks Investment Research

REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie

REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.

Other symbols:ABBV
4 months ago - Zacks Investment Research

REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?

REGENXBIO (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th...

4 months ago - Zacks Investment Research

Eyes Have It in AbbVie Deal With Regenxbio

To expand its footprint in eye care, AbbVie Inc.( ABBV , Financial) has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-area ...

Other symbols:ABBV
4 months ago - GuruFocus

Why Regenxbio Stock Is Way Up Today

American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration.

4 months ago - The Motley Fool